Immuno-Oncology Small Molecule Therapies
Immuno-oncology (IO) therapies have revolutionized anti-cancer therapies in the past a few years. The drugs can harness the innate power of human immune system to selectively eradicate cancer cells by activating tumor-specific immune response while sparing toxicity on normal cells caused by traditional targeted or chemotherapies. Several therapeutic antibodies against immune checkpoint receptors and ligands, such as PD1, CTL4 and PD-L1, have demonstrated striking and durable clinical responses across many types of tumors and become billion-dollar blockbusters. Abbisko is developing a pipeline of the next-generation small molecule immune modulators to improve efficacy, overcome resistance, reduce side effects, and synergize with first generation IO agents.